LB Pharmaceuticals Inc filed its Form 10-Q with the SEC on August 11, 2026, covering the quarterly period ended June 30, 2026, and reporting 32,259,175 shares of common stock outstanding as of August 5, 2026.

Key Highlights

  • Shares outstanding: LB Pharmaceuticals reported 32,259,175 shares of common stock outstanding as of August 5, 2026.
  • Company classification: The registrant is identified in the filing as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
  • Lead product candidate: The filing identifies LB-102 as the company's primary drug candidate, with development and regulatory submissions described as ongoing.
  • Shell company status: The filing indicates the registrant is not a shell company as defined under Rule 12b-2 of the Exchange Act.
  • Listing: Common stock, $0.0001 par value, is listed on The Nasdaq Stock Market LLC under the symbol LBRX (NASDAQ:LBRX).
  • Filing compliance: According to the filing, the company has filed all required reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.

LB Pharmaceuticals and LB-102 Development Status in Q2 2026

LB Pharmaceuticals Inc, a Delaware-incorporated biopharmaceutical company headquartered at One Pennsylvania Plaza, Suite 1025, New York, NY 10119, filed its quarterly report for the period ended June 30, 2026. The company trades on NASDAQ:LBRX and carries Commission File Number 001-42831. According to the filing, LB-102 is the company's central product candidate, with the company disclosing intentions to pursue Investigational New Drug applications, New Drug Applications, and other regulatory submissions in connection with its development program.

The filing describes several areas of focus for LB-102, including the "initiation, timing, progress, potential registrational quality, and results" of research and development programs, preclinical studies, and clinical trials. The company also disclosed forward-looking considerations around its "ability to reproducibly predict treatment outcomes for LB-102 amongst identified patient populations." The filing notes the company's reliance on third-party manufacturers and service providers for production and scale-up of its drug product, and it flags the ability to attract funding for operations as a key consideration for further development and potential commercialization of LB-102, if approved.

The quarterly report also addresses intellectual property, workforce, and regulatory factors. The company disclosed plans related to establishing and maintaining "strategic collaborations, licensing, or other arrangements," as well as the potential to identify additional indications for LB-102 beyond those currently under study. All forward-looking statements in the filing are the company's own and are subject to the cautionary language set forth in the report, which notes that "actual future results may be materially different from any future results expressed or implied by these forward-looking statements."

What Was Disclosed

LB Pharmaceuticals Inc submitted its Form 10-Q for the quarter ended June 30, 2026, disclosing 32,259,175 shares outstanding, its emerging growth company status, and the continued development of its lead candidate LB-102, including ongoing regulatory and manufacturing activities.